SynthesisDisease markers2020
The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis.
Synthesis in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Prognostic Role of the C-Reactive Protein/Albumin Ratio in Patients With Gynecological Cancers: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Baseline Nutritional Status and Early Treatment Response in Oropharyngeal Cancer: A Prospective Cohort Study by HPV Status (FIS 19 Study).Nutrients · 2026Observational
- Albumin-Anchored Composite Ratios of Blood Urea Nitrogen, C-Reactive Protein, Lactate, and Creatinine for Predicting Mortality in Chronically Ill Intensive Care Unit Patients.Journal of clinical medicine · 2026Article
- Primary Dedifferentiated Liposarcoma of the Duodenum with Intestinal Bleeding: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data.Cancers · 2024Article
- The Prognostic Value of Serum Biomarkers for Survival of Children with Osteosarcoma of the Extremities.Current oncology (Toronto, Ont.) · 2023Article
- Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy.Scientific reports · 2023Article
- Inflammatory prognostic scoring systems are risk factors for surgical site infection following wide local excision of soft tissue sarcoma.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2022Article
- Analysis of prognostic factors in soft tissue sarcoma: Cancer registry from a single tertiary hospital in Indonesia. A retrospective cohort study.Annals of medicine and surgery (2012) · 2020Article
- Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma.Cancer management and research · 2020Article
- C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights.Frontiers in immunology · 2020Review
- Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis.Frontiers in immunologyReview
- Role of the Prognostic Nutritional Index in Patients With Soft-tissue Sarcoma.In vivo (Athens, Greece)Article
- Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsBoth pretreatment serum CRP (C-reactive protein) level and ALB (albumin) level have been found to be predictive of survival for multiple malignancies including sarcoma. Since both of the GPS (Glasgow prognostic score) and CAR (C-reactive protein to albumin ratio) are based on the combination of CRP and ALB, we conducted a meta-analysis to evaluate the prognostic role of these two parameters for sarcoma patients.
methodsA detailed literature search was conducted in MEDLINE, Embase, and Cochrane Library for relevant research publications written in English. Patients' clinical characteristics, outcomes of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were extracted. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were combined to evaluate the prognostic role of GPS or CAR.
resultsTwelve articles containing 2695 patients were identified as eligible studies. The results showed that an elevated GPS was significantly correlated with poor OS (HR = 2.42; 95% CI: 1.98-2.94;
conclusionAn elevated GPS is predictive of poor survival in patients with sarcomas and is promising to be used as a factor for risk stratification. A higher CAR value is also predictive of poor survival; however, the optimal CAR cut-off value is still to be determined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.